68
RBC Bioscience Corporation
6848.TWO · TWO
$21.90 +1.15% (+$0.25)
1M +9.62%
Market Cap $312.6M
P/E Ratio 13.28x
Div. Yield 5.48%
ROE 9.07%
Bulios Fair Price
$30.86
40.9% upside
Current Price
$21.9
Undervalued Fair Value Overvalued
According to Bulios Fair Price, 6848.TWO is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
83 /100
Cheap P/E 13.28x
EV/EBITDA 13.05x
P/S 1.42x
Growth
73 /100
Growing EPS growth 78.16%
Rev. growth 8.11%
Book val. growth 2.58%
Profitability
77 /100
Strong Gross margin 42.14%
Net margin 10.72%
Op. margin 15.94%
Quality
29 /100
Poor ROIC 4.18%
ROE 9.07%
ROA 3.25%
Debt
28 /100
High Debt/Equity 1.46x
Current ratio 1.25x
Int. coverage 3.61x
Stability
56 /100
Moderate Beta 0.41x
Rev. volatility 9.98%
EPS volatility 100.91%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about 6848.TWO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Mingwei Zhuo
Employees
50
Headquarters
New Taipei City